Cargando…
Updated consensus statements on COVID-19 Vaccine Allergy Safety in Hong Kong
Due to global concerns over coronavirus disease 2019 (COVID-19) vaccine-associated allergic reactions; the Hong Kong Institute of Allergy (HKIA) formulated an initial set of consensus statements (CS) on COVID-19 Vaccine Allergy Safety (VAS) in early 2021. Following accumulation of both local and int...
Autores principales: | Chiang, Valerie, Leung, Agnes S.Y., Au, Elaine Y.L., Ho, Marco H.K., Lee, Tak Hong, Wu, Adrian Y.Y., Wong, Gary W.K., Li, Philip H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asia Pacific Association of Allergy, Asthma and Clinical Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819424/ https://www.ncbi.nlm.nih.gov/pubmed/35174059 http://dx.doi.org/10.5415/apallergy.2022.12.e8 |
Ejemplares similares
-
Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong
por: Chiang, Valerie, et al.
Publicado: (2021) -
Hong Kong Drug Allergy Delabelling Initiative (HK-DADI) consensus statements for penicillin allergy testing by nonallergists
por: Li, Philip H., et al.
Publicado: (2022) -
Hong Kong Anaphylaxis Consortium Consensus Statements on prescription of adrenaline autoinjectors in the acute care setting
por: Li, Philip H., et al.
Publicado: (2021) -
Consensus statements on the clinical understanding and use of bupropion in Hong Kong
por: Lee, Wing‐King, et al.
Publicado: (2021) -
Experience of the first 1127 COVID-19 Vaccine Allergy Safety patients in Hong Kong – Clinical outcomes, barriers to vaccination, and urgency for reform()
por: Chiang, Valerie, et al.
Publicado: (2021)